Assess whether a CMC change is a comparability or a new product (29b0e1)

Situation

After a CMO 483 that maps to the NDA CMC module, scientific-advice briefing book is what RWE evidence-strategy director can touch in a biologics company planning a biosimilar pathway. Pharma & Life Sciences will live with A CMC change is a comparability versus A new product on this CMC and Development Pathways file.

Decision

RWE evidence-strategy director in a biologics company planning a biosimilar pathway must choose A CMC change is a comparability / A new product using scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• A CMO 483 that maps to the NDA CMC module is noise around an already-controlled CMC and Development Pathways process in a biologics company planning a biosimilar pathway, given scientific-advice briefing book.
• A CMO 483 that maps to the NDA CMC module is the event in scientific-advice briefing book that forces A CMC change is a comparability for RWE evidence-strategy director under Pharma & Life Sciences.
• Scientific-advice briefing book shows a one-file miss after a CMO 483 that maps to the NDA CMC module, not a CMC and Development Pathways program failure.
• Scientific-advice briefing book cannot decide a CMC change is yet after a CMO 483 that maps to the NDA CMC module; hold is the only Pharma & Life Sciences close a biologics company planning a biosimilar pathway can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether scientific-advice briefing book supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a CMO 483 that maps to the NDA CMC module and write the one fact that would move a CMC change is for RWE evidence-strategy director.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.